Skip to main content
SpringerLink
Log in

Intravenous Radiopeptide Infusions with High Activity of 111In-Octreotide

  • Chapter
  • First Online:
Liver Intra-arterial PRRT with 111In-Octreotide

  • 229 Accesses

Abstract

Radiopeptide intravenous infusions were first introduced in 1996 as a new treatment approach to confront particularly unresectable liver metastatic lesions of neuroendocrine character by Eric Krenning et al. Peptide Receptor Radionuclide Therapy (PRRT) using 111In-Octreotide in high doses got included in the routine activities of the Nuclear Medicine Section of the “Aretaieion” University Hospital since 1997, and they have been using it to treat tumours of neuroendocrine character for more than 15 years now in close cooperation with the Interventional Radiology Section (Prof. L. Vlahos, Prof. D. Mourikis and Prof. A. Chatziioannou). This radionuclide novelty was performed almost exclusively intra-arterially by being focused on the liver metastases of this rare neoplastic disease. However, some liver metastases cases could not be treated intra-arterially either because the patient refused to accept to be catheterised or the anatomic variants of the arterial net inhibited the intra-arterial approach. In such cases, PRRT was performed intravenously. This chapter covers, in detail, a study of intravenous administration of PRRT to a cohort of ten patients suffering from liver metastasised neuroendocrine tumours (NETs) and the results of the study.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–43.

    Article  CAS  Google Scholar 

  2. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–996.

    CAS  PubMed  Google Scholar 

  3. Padhani A, Ollivier L, Ihse I, Persson B, et al. Neuroendocrine metastases of the liver. World J Surg. 1995;19:76–82.

    Article  Google Scholar 

  4. Neary PC, Redmond PH, Houghton T, et al. Carcinoid disease: review of the literature. Dis Colon Rectum. 1997;40:349–62.

    Article  CAS  Google Scholar 

  5. Diaco DS, Hajarizadeh H, Mueller CR, et al. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg. 1995;169:523–8.

    Article  CAS  Google Scholar 

  6. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397–403.

    Article  CAS  Google Scholar 

  7. Diculescu M, Atanasiu C, Arbanas T, et al. Chemoembolization in the treatment of metastatic ileocolic carcinoid. Rom J Gastroenterol. 2002;11:141–7.

    PubMed  Google Scholar 

  8. O’Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive neuroendocrine tumors. Endocr Relat Cancer. 2003;10:463–8.

    Article  Google Scholar 

  9. Krenning EP, Kooij PPM, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D.Phe1]—octreotide; a case history. Ann N Y Acad Sci. 1994;733:496–506.

    Article  CAS  Google Scholar 

  10. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1] and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.

    Article  CAS  Google Scholar 

  11. Adelstein SJ. The Auger process: a therapeutic promise? AJR. 1993;160:707–13.

    Article  CAS  Google Scholar 

  12. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogues for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23–9.

    Article  Google Scholar 

  13. Wiseman GA, Kvols LK. The radiolabelled MIBG and Somatostatin analogues. Semin Nucl Medicine XXV. 1995;3:272–8.

    Article  Google Scholar 

  14. De Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and Indium-111 labeling, receptor binding and biodistribution of [DOTA, D-Phe1, Tyr3]-octreotide; a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–71.

    PubMed  Google Scholar 

  15. Limouris GS, Lyra M, Skarlos D, et al. Electron therapy with In-111 pentetreotide in hepatocellular carcinoma. In: Bergmann H, Köhn H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research XXIII. Birkhäuser, Basel: Advances in Pharmacological Sciences; 1999.

    Google Scholar 

  16. Limouris GS, Voliotopoulos V, Dimitropoulos N, et al. Auger-electron therapeutic effectiveness in neuro-endocrine and non-tumors using indium-111 labeled pentetreotide. Nucl Med Commun. 2000;21(6):590. [abstr]

    Article  Google Scholar 

  17. Hirmas N, Jadaan R, Al-Ibraheem A. Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives. Nucl Med Mol Imaging. 2018;52(3):190–9.

    Article  CAS  Google Scholar 

  18. Yao JC, Hassan M, Phan A. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  Google Scholar 

  19. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.

    Article  Google Scholar 

  20. Rindi G, Klöppel G, Alhman H. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.

    Article  CAS  Google Scholar 

  21. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62.

    Article  CAS  Google Scholar 

  22. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121:1172–86.

    Article  CAS  Google Scholar 

  23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  Google Scholar 

  24. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74(887):983–6.

    Article  CAS  Google Scholar 

  25. Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In- 111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35:1827–37.

    Article  CAS  Google Scholar 

  26. Lafortune M, Mardore F, Patriquin H, et al. Segmental anatomy of the liver; a US approach to the Couinaud nomenclature. Radiology. 1991;181:443–8.

    Article  CAS  Google Scholar 

  27. Couinaud C. Le Foie. Etudes anatomiques et chirugicales. Paris: Masson & Cie; 1957.

    Google Scholar 

  28. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460–46.

    Article  Google Scholar 

  29. Bison SM, Konijnenberg MW, Melis M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2(1):55–66.

    Article  Google Scholar 

  30. Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: a glimpse into the future. World J Gastrointest Oncol. 2017;9(1):4–20.

    Article  Google Scholar 

  31. Senekowitsch-Schmidtke R, Huber R, Seidl C. Alpha-emitting radionuclides for therapy in oncology. In: Limouris GS, Biersack H-J, Shukla SK, editors. Radionuclide therapy for oncology, current status and future aspects. Athens: Mediterra; 2003. p. 135–40.

    Google Scholar 

  32. Tiensuu Janson E, Eriksson B, Oberg K. Treatment with high dose [(111) In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors–evaluation of therapeutic and toxic effects. Acta Oncol. 1999;38(3):373–7.

    Article  CAS  Google Scholar 

  33. Caplin ME, Miclcarek W, Buscombe JR, et al. Toxicity of high-activity In-111 octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun. 2000;21:97–102.

    Article  CAS  Google Scholar 

  34. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–22.

    Article  Google Scholar 

  35. Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–32.

    Article  Google Scholar 

  36. Buscombe JR, Caplin ME, Hilson AJW. Long-term efficacy of high-activity 111In-pente-treotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44(1):1–6.

    CAS  PubMed  Google Scholar 

  37. Nguyen C, Faraggi M, Giraudet A-L. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med. 2004;45:1660–8.

    CAS  PubMed  Google Scholar 

  38. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008;23:292–300.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

Authors
  1. Georgios S. Limouris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios S. Limouris .

Editor information

Editors and Affiliations

  1. Nuclear Medicine, Medical School National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Limouris, G.S. (2021). Intravenous Radiopeptide Infusions with High Activity of 111In-Octreotide. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70773-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70772-9

  • Online ISBN: 978-3-030-70773-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation